Eurograd message

                --Apple-Mail=_A7BB10FE-EE25-4115-9CD8-977ED7947FC6
Content-Transfer-Encoding: quoted-printable
Content-Type: text/plain;
	charset=us-ascii

Dear all,

We invite contributions to our open panel 004.The futures of and in =
Genomics  at =
the 2022 EASST Conference in Madrid (July 6-9). Convened by Violeta =
Argudo-Portal and Mauro Turrini (Institute of Public Goods and Policies, =
Spanish National Research Council).

Abstract:
The dramatic fall in the price and cost of genomics testing has made =
possible a practice that seemed to be confined to the laboratory until a =
few years ago. Testing one's DNA, or that of beings close to us is an =
increasingly widespread and almost trivialised possibility. Particularly =
in the reproductive sphere, where non-invasive prenatal testing, =
pre-conception or gamete donor screening are emerging, but also more =
simply with the use of direct-to-consumer genetic tests that can =
investigate susceptibility to diseases, food intolerances, allergies, =
and so on. A common element of these tests is that they use genomics to =
anticipate the future in different ways: to predict the possibility of a =
genetic mutation in a couple before conception, to identify the presence =
of a chromosomal/genetic disorders in a foetus before it to be born, or =
the predisposition to a common, multi-factorial disease before its =
onset. The relationship with the future is certainly one of the aspects =
that makes genomics as much promising as controversial, if not even =
disturbing.  That is why this panel aims to ignite a conversation around =
the question: what are the futures embedded in genomics?=20
The possibility of a disease-free future comes along with the threat of =
discriminating on the basis of DNA and, more generally, with the =
imperative of knowledge-based management to optimise risk. While =
healthcare systems are extremely cautious about these tests, whose =
clinical usefulness they often dispute, their main driving forces are =
clinics, laboratories, or private companies whose commercial strategies =
rely on the symbolic power of the genome. In this space, situated on the =
fringes or outside the national healthcare services or the medical =
establishment, the access rules to human constitutional DNA are =
reconfigured and rooted in the very materiality of the technology used. =
These types of highly routinised testing practices make use of a wide =
range of devices that, for instance, analyse genomes through panels of =
pre-set DNA variants or segments in a quasi-automatized way. As these =
panels incorporate the medical decision of what regions of DNA are worth =
being analysed, they are the object of debate of international, =
national, or local ethics committees, and medical associations. Also, =
like many other classification systems, they tend to crystallize into =
standards that compete in crafting the future of genomics. In this =
panel, we welcome contributions aiming to explore how these futures =
embedded in genomics reconfigure practices of consumption and =
subjectification, discourses and imaginaries of health and well-being, =
systems of regulation of access to DNA, and the production of testing =
devices. We are also open to submissions delving into the =
more-than-human confines, where genetic testing or screening are used on =
embryos, foetuses, or non-human animals such as companion animals or =
farm animals.=20

Deadline: February 1st.=20

Information about the call for submissions can be found here: =
https://easst2022.org/callforsubmissions.asp and the full abstract here: =
https://easst2022.org/IMAGENES/panelsResultados/004.pdf

Contact person: violeta.argudo@csic.es (Violeta Argudo-Portal).

With best wishes,
Violeta Argudo-Portal and Mauro Turrini



--Apple-Mail=_A7BB10FE-EE25-4115-9CD8-977ED7947FC6
Content-Transfer-Encoding: quoted-printable
Content-Type: text/html;
	charset=us-ascii

Dear =
all,We invite =
contributions to our open panel 004.The futures of and in Genomics at the 2022 EASST =
Conference in Madrid (July 6-9). Convened by Violeta Argudo-Portal =
and Mauro Turrini (Institute of Public Goods and =
Policies, Spanish National Research =
Council).Abstract:The
dramatic fall in the price and cost of genomics testing has made =
possible a
practice that seemed to be confined to the laboratory until a few years =
ago.
Testing one's DNA, or that of beings close to us is an increasingly =
widespread
and almost trivialised possibility. Particularly in the reproductive =
sphere,
where non-invasive prenatal testing, pre-conception or gamete donor =
screening
are emerging, but also more simply with the use of direct-to-consumer =
genetic
tests that can investigate susceptibility to diseases, food =
intolerances, allergies,
and so on. A common element of these tests is that they use genomics to
anticipate the future in different ways: to predict the possibility of a =
genetic
mutation in a couple before conception, to identify the presence of a
chromosomal/genetic disorders in a foetus before it to be born, or the
predisposition to a common, multi-factorial disease before its onset. =
The relationship
with the future is certainly one of the aspects that makes genomics as =
much promising
as controversial, if not even disturbing.  That is why this panel =
aims to ignite a
conversation around the question: what are the futures embedded in =
genomics? The
possibility of a disease-free future comes along with the threat of
discriminating on the basis of DNA and, more generally, with the =
imperative of
knowledge-based management to optimise risk. While healthcare systems =
are
extremely cautious about these tests, whose clinical usefulness they =
often
dispute, their main driving forces are clinics, laboratories, or private
companies whose commercial strategies rely on the symbolic power of the =
genome.
In this space, situated on the fringes or outside the national =
healthcare
services or the medical establishment, the access rules to human =
constitutional
DNA are reconfigured and rooted in the very materiality of the =
technology used.
These types of highly routinised testing practices make use of a wide =
range of devices
that, for instance, analyse genomes through panels of pre-set DNA =
variants or
segments in a quasi-automatized way. As these panels incorporate the =
medical
decision of what regions of DNA are worth being analysed, they are the =
object
of debate of international, national, or local ethics committees, and =
medical
associations. Also, like many other classification systems, they tend to =
crystallize
into standards that compete in crafting the future of genomics. In this =
panel,
we welcome contributions aiming to explore how these futures embedded in
genomics reconfigure practices of consumption and subjectification, =
discourses
and imaginaries of health and well-being, systems of regulation of =
access to
DNA, and the production of testing devices. We are also open to =
submissions
delving into the more-than-human confines, where genetic testing or =
screening are
used on embryos, foetuses, or non-human animals such as companion =
animals or
farm animals. Deadline: =
February 1st. Information about the call for =
submissions can be found here: https://easst2022.org/callforsubmissions.asp and the full =
abstract here: https://easst2022.org/IMAGENES/panelsResultados/004.pdfContact =
person: violeta.argudo@csic.es (Violeta Argudo-Portal).With best =
wishes,Violeta Argudo-Portal and Mauro =
Turrini



=

--Apple-Mail=_A7BB10FE-EE25-4115-9CD8-977ED7947FC6--